In this study, we aimed to show whether NSE, S100B, MAPT, and GFAP levels would provide evidence of early neurological damage in premature infants receiving postnatal low-dose dexamethasone therapy to treat BPD. The gene discussed is MAPT; the disease is bronchopulmonary dysplasia.